Advertisement
Singapore markets closed
  • Straits Times Index

    3,287.75
    -5.38 (-0.16%)
     
  • S&P 500

    5,010.26
    -61.37 (-1.21%)
     
  • Dow

    37,873.03
    -587.89 (-1.53%)
     
  • Nasdaq

    15,450.95
    -261.80 (-1.67%)
     
  • Bitcoin USD

    63,870.36
    -1,070.73 (-1.65%)
     
  • CMC Crypto 200

    1,375.61
    -6.96 (-0.50%)
     
  • FTSE 100

    8,076.24
    +35.86 (+0.45%)
     
  • Gold

    2,346.00
    +7.60 (+0.33%)
     
  • Crude Oil

    82.21
    -0.60 (-0.72%)
     
  • 10-Yr Bond

    4.7020
    +0.0500 (+1.07%)
     
  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     
  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     
  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     
  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     
  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Discussing Teva’s Recent Stock Performance

Discussing Teva’s Recent Stock Performance

On March 20, 2018, Teva Pharmaceutical (TEVA) ended the trading day at a closing price of $17.68. Recently, on February 15, 2018, TEVA stock registered a rise of ~10.5% triggered by the news of an investment of $358 million in the company by Berkshire Hathaway. This news led to the market’s gaining some confidence in the troubled stock, as Berkshire Hathaway investments have been synonymous with value investments.